Biotech's New Rules: Data, Discipline and the Return of Capital in 2026
核心洞察
After the 2022 reset, biotech capital has returned through 2025-2026, but with stricter conditions favoring late-stage, data-rich companies over early-stage promise.
Follow-on equity issuance reached roughly $56 billion in 2025, with nearly 90% of life sciences IPO issuers in Phase 2 or later, signaling a market that demands de-risked assets.
Cross-border out-licensing from Greater China hit approximately $138 billion in 2025, nearly ten times the 2021 figure, with China now accounting for roughly 30% of the global clinical pipeline.
After several years of volatility, biotechnology financing has returned—but under very different rules. Investors are increasingly focused on data, defined catalysts, and disciplined execution, while cross-border partnerships and strategic transactions are playing a larger role in value creation. David H. Crean, Chief Business Officer of MediciNova, offered an in-depth perspective on the changing investment landscape, regulatory influences, and emerging opportunities in neuroscience and rare disease development in a conversation with BioSpectrum Asia at the BIO International Convention 2026.
The Financing Window Reopens—With Conditions
The window has reopened, but it reopened with conditions. After the 2022 reset, capital returned to clinical-stage biotechnology through 2025 and into 2026, and the clearest signal sits in the secondary market. Follow-on equity issuance ran to roughly $56 billion in 2025, with demand concentrated in companies carrying credible clinical data. IPOs are coming back, but the bar has moved. Close to 90 percent of life sciences IPO issuers last year were in Phase 2 or later.
"The market is looking for de-risk stories, buying proof, not promise," Crean said. Underneath the recovery sits a split that every clinical-stage leader should read carefully. Late-stage, de-risked assets attract large sums of capital and premium valuations. A long tail of small-cap companies trades at or below cash, with negative enterprise value, unable to convert good science into investor conviction. The same index (XBI) that fell to an 18-month low after the April 2025 tariff announcement rose roughly 75 percent by December. "That is recovery and dispersion at the same time," Crean noted.
What clears the bar now is specific: blue-chip and insider support, a defined value catalyst inside 12 to 18 months, and a mechanism a generalist can underwrite without a PhD. Generalist investors have started to re-engage, and certain therapeutic areas—neurology and cardiometabolic among them—have drawn fresh capital after a decade on the margins.
Capital Efficiency as Strategy
For a company like MediciNova, the discipline writes itself. "Capital efficiency is not a buzzword. It is a financing strategy," Crean emphasized. The company runs a lean operating structure and advances a meaningful share of its clinical work through investigator-sponsored trials funded by government and institutional grants. Its large-scale Expanded Access Program in ALS (搜索), the SEANOBI study, is supported by an NIH and NINDS grant under the ACT for ALS initiative, which allows the company to generate real-world clinical and biomarker data while limiting dilutive equity financing.
A small-molecule pipeline with manageable cost of goods and clear inflection points is easier to fund than a capital-intensive platform selling optionality. "The companies that raise well in 2026 are the ones that can name the catalyst, name the date, and show why the data will move the price," Crean said.
Dealmaking Trends: Bolt-Ons and Cross-Border Flows
Business development has moved from optionality to a requirement, driven by two forces. Large pharma faces a loss-of-exclusivity wall on the order of $200 billion in branded revenue this decade, and the cash to fill it is sitting on the balance sheet. The result is the most active dealmaking environment since before the pandemic.
The mega-merger is out of favor. Buyers have settled on bolt-on acquisitions, generally in the $1 billion to $5 billion range, aimed at one or two assets with validated biology and a clear regulatory path. Contingent value rights and milestone-weighted terms are now standard, bridging the gap between what a seller believes and what a buyer will underwrite before the next readout.
The second force is geographic. China has moved from manufacturing hub to innovation source. Cross-border out-licensing from Greater China reached roughly $138 billion in 2025, close to ten times the 2021 figure, and 2026 is on pace to surpass it. China now accounts for something near 30 percent of the global clinical pipeline. AstraZeneca, GSK, Roche, and Merck have all signed multi-billion-dollar agreements with Chinese biotechs. The NewCo structure, which pairs an Asia-origin asset with Western capital and management, has become a repeatable model rather than an experiment.
The rest of Asia-Pacific is building deliberately. South Korea is landing blood-brain-barrier and ADC licensing deals and scaling translational funding. Japan's Sakigake designation and bioventure programs shorten the road for promising therapies. "Partner from a position of data, not desperation, and structure the deal so the value follows the result," Crean advised.
Regulatory Dynamics: Signals in Both Directions
Regulation has become a primary input to valuation, not a downstream formality. Investors now price the regulatory path and the agency as directly as they price the science, and 2026 has given them reasons in both directions.
The constructive signal is the continued application of the accelerated approval pathway to serious rare disease. In April 2026, the FDA cleared Denali (搜索)'s tividenofusp alfa for the neuronopathic form of Hunter syndrome (搜索) on a biomarker surrogate—a reduction of roughly 90 percent in cerebrospinal fluid heparan sulfate—with clinical confirmation to follow. "For developers of brain-penetrant therapies in rare neurological disease, that decision matters beyond the single drug. It signals that a well-qualified surrogate, tied credibly to clinical benefit, can still carry an approval," Crean said.
The countervailing signal is unpredictability itself. Leadership turnover at the FDA, debate over the future of advisory committees, and inconsistent benefit-risk calls have introduced risk that appears on no term sheet. "Capital does not flee risk. Capital flees risk it cannot price," Crean observed.
Alongside that caution, there is real openness to better methods. Regulators are increasingly receptive to Bayesian and adaptive designs and to validated biomarkers such as neurofilament light (搜索) as a measure of axonal injury, provided they are prospectively justified and transparent.
For MediciNova, that logic runs straight through its lead program. MN-166 (ibudilast) holds Orphan Drug and Fast Track designations from the FDA and Orphan designation from the European Commission in ALS (搜索). The company built COMBAT-ALS, its Phase 2b/3 trial, to produce the controlled evidence a full approval requires. The NIH-funded SEANOBI Expanded Access Program runs alongside it, capturing neurofilament and clinical data in patients ineligible for the randomized trial. "Regulatory strategy does not begin at the pre-NDA meeting. It is a design choice made at the moment of first dosing, and increasingly it is the variable that decides whether an asset is financeable at all," Crean said.
Neurology and Rare Disease: The Evidentiary Challenge
The hardest problems in neurology and rare disease are not commercial—they are evidentiary. Three challenges separate the programs that reach approval from those that stall.
The first is the endpoint. Neurological diseases often progress slowly, vary widely between patients, and inflict damage that is irreversible by the time of diagnosis. In conditions such as ALS (搜索) and progressive MS, functional scales like the ALSFRS-R carry real variability, and a clinical endpoint built on slow functional decline can require large trials over long horizons. This is why biomarker-driven development has moved from preference to necessity.
The second is the patient population and the operational burden that comes with it. Rare disease trials compete for small, geographically scattered cohorts, often against multiple sponsors pursuing the same indication. A patient-centric protocol minimizes unnecessary visits and favors accessible routes of administration. "An oral small molecule carries a clear logistical advantage here over a biologic or gene therapy that requires institutional infusion infrastructure," Crean noted.
The third is translation across regions. A late-stage neurology program increasingly runs as a multi-regional trial, which raises questions of endpoint harmonization, ethnic sensitivity, and acceptance of foreign data by the FDA, EMA, NMPA, and PMDA.
Underlying all three is capital intensity. Late-stage neurologic trials are long, expensive, and difficult to finance. "None of this is solved with capital alone. It is solved with trial design that respects the biology, a biomarker strategy agreed with regulators early, and an advocacy partnership built years before the pivotal readout," Crean said.
Where Value Will Concentrate
Value will concentrate where unmet need, scientific tractability, and a financeable path intersect. Four areas stand out.
Neuroscience is the clearest. After years on the periphery of investor interest, the field is drawing capital again, helped by approvals that validate brain-penetrant mechanisms and by biomarkers that let developers measure central nervous system engagement. Conditions such as ALS (搜索), progressive multiple sclerosis, Alzheimer's disease, and the broader neurodegenerative set carry enormous unmet need and increasingly tractable endpoints. Small molecules retain a structural advantage in the brain, where crossing the blood-brain barrier remains the gating problem for many modalities.
Rare disease is the second. The regulatory framework still rewards well-designed programs in severe conditions with no alternatives, and the biomarker toolkit that makes those programs feasible continues to improve. The opportunity is not limited to genetic medicines—small molecules, reformulated or repurposed agents, and anti-inflammatory approaches can all play a role.
The third is the corridor between Asian innovation and Western capital. The asset flow out of China, Korea, and Japan is no longer a curiosity but a structural feature of the industry. Value accrues to the parties who can bridge the two systems.
The fourth is the capital-efficient operating model. "Companies that convert each dollar into clear de-risking milestones, rather than diffuse optionality, will out-raise and out-last those that do not," Crean said.
"The opportunity in biotechnology is not to chase what is fashionable. It is to advance programs where the science is credible, the need is real, and the development strategy can withstand scrutiny from regulators, partners, investors, physicians, and patients. Capital is available again for that kind of company."